Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of aH5N8c and aH5N6c Influenza Vaccines
NCT05874713Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of aH5N8c, MF59-adjuvanted H5N6 cell culture-derived influenza vaccine in Influenza A virus H5N8 subtype (H5N8), Influenza A virus subtype H5N6 infection (H5N6), sponsored by CSL Seqirus. Started Jun 2023; status: completed.
02
Drugs
aH5N8cMF59-adjuvanted H5N6 cell culture-derived influenza vaccine
03
Conditions
Influenza A virus H5N8 subtype (H5N8)Influenza A virus subtype H5N6 infection (H5N6)
Beyond the preview
Go deeper on NCT05874713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874713.